nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-4CB61075·Framework v5.10·Pipeline v0.4·Evaluated 02 Nov 2026·OECD: 3.2 Clinical medicine·Basis: Full text·Type: Randomized controlled trial

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

Timothy Craig et al.Timothy Craig, Markus Magerl, Donald S Levy et al.·2022·10.1016/s0140-6736(21)02225-x ↗

Primary claim

Compared with placebo, the rate of attacks was significantly reduced with garadacimab at 200 mg (reduced by 100% [95% CI 98–101]; p=0·0002) and 600 mg (reduced by 93% [54–110]; p=0·0003).

Supported · large randomized effects over 12 weeks, with small treatment arms limiting precision
In brief

Garadacimab establishes placebo-controlled proof of concept for FXIIa-targeted HAE prophylaxis, but the small, 12-week trial leaves definitive benefit–risk assessment unresolved.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract not available — view at DOI ↗

Key Claims

Primary finding · Supported

Compared with placebo, the rate of attacks was significantly reduced with garadacimab at 200 mg (reduced by 100% [95% CI 98–101]; p=0·0002) and 600 mg (reduced by 93% [54–110]; p=0·0003).

Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

large randomized effects over 12 weeks, with small treatment arms limiting precision

Summary, Findings
Quote verified
Secondary · Supported

Across all treatment groups, no serious adverse events or adverse events of special interest (ie, anaphylaxis, thromboembolic events, or bleeding) were observed, showing that subcutaneous treatment with garadacimab was well tolerated for up to 12 weeks.

systematic short-term observation with too few treated patients to exclude uncommon harms

Discussion, paragraph beginning ‘Across all treatment groups’
Quote verified
Secondary · Supported

All eight patients (100%) treated with 200 mg garadacimab had a reduction in the number of monthly attacks of at least 90% and seven (88%) were attack free (figure 3).

directly reported response counts from an eight-person treatment arm

Results, paragraph beginning ‘During the 12-week subcutaneous period’
Quote verified
Secondary · Tentative

Therefore, in our study, maximal efficacy was at 200 mg every 4 weeks, and an increase to 600 mg did not appear to result in an increase in efficacy.

no powered active-dose comparison established maximal efficacy at 200 mg

Discussion, paragraph beginning ‘Although we observed improved efficacy and safety’

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Controlled evidence validates a distinct target

The trial demonstrates large placebo-controlled reductions in attacks with FXIIa inhibition, extending the clinical evidence beyond existing C1-INH and kallikrein-directed approaches.

↳ Research in context; Results, primary efficacy analysis

#methodological rigour

Concealed allocation and complete efficacy accounting

Interactive-response allocation, masked participants and investigators, volume-normalised syringes, and complete ITT attack-rate data protect the primary comparison from avoidable execution bias.

↳ Methods, Randomisation and masking; Statistical analysis

#methodological rigour

Systematic assessment of short-term treatment harms

Adverse events were defined, MedDRA-coded, and assessed alongside special-interest events, laboratory findings, and anti-drug antibodies. Table 2 reports events and patient denominators by treatment group.

↳ Methods, Procedures and Outcomes; Table 2

Limitations

#methodological rigour

Small arms and short observation constrain inference

Only seven to nine participants were assigned to each arm, with 12 weeks of blinded subcutaneous treatment. This limits effect-size precision and assessment of durable benefit or uncommon harms.

↳ Results, randomized population; Discussion, limitations paragraph

#reporting

Preferred dose lacks direct comparative confirmation

The claim of maximal efficacy at 200 mg rests on numerical response differences and post-hoc modelling rather than a powered active-dose comparison. The observed non-monotonic response leaves dose selection unresolved.

↳ Discussion, dose-response and optimal-benefit–risk paragraphs

#positioning

Comparative positioning remains largely feature based

The discussion emphasises mechanism and dosing convenience without quantitatively comparing benefit–risk against licensed prophylactic alternatives. Those features establish differentiation, not comparative superiority.

↳ Research in context; Discussion, prophylactic alternatives paragraph

Does this match your read? Add your assessment ↓

Nabu Commentary

Concealed randomisation, masking, complete ITT attack-rate data, and prespecified placebo comparisons support the large efficacy signal. The mechanistically distinct intervention provides clinical target validation, but seven to nine patients per arm and 12 weeks of treatment cannot establish durable benefit or uncommon harms. The Discussion's preference for 200 mg is less secure than the primary efficacy finding because direct active-dose comparisons were not powered and supporting modelling was post hoc. The limitations are connected to generalisability and long-term inference, while positioning against existing prophylaxis remains mostly feature-based. Confidence intervals extending above 100% reduction and the incorrect male percentage are reporting notes that do not overturn the central results.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
4.0±0.2

Contribution
4.1

The randomized trial supplies clinical proof of concept for an upstream FXIIa-targeted prophylactic mechanism distinct from C1-INH and kallikrein-directed approaches. Small arms, short follow-up, and unresolved active-dose comparisons constrain the advance to target validation rather than definitive treatment positioning.

Research in context; Results, primary efficacy analysis; Discussion, dose-selection paragraphs
Methodological Rigour
4.0

Central allocation concealment, participant and investigator masking, complete ITT attack-rate data, multiplicity-controlled primary comparisons, and systematic harms collection support the execution score. Arms of seven to nine patients, baseline variation, limited duration, and imprecise interval presentation constrain precision and dose-selection inference.

Methods, Randomisation and masking and Statistical analysis; Tables 1–2; Results, primary efficacy analysis
Reporting
4.0

The article separates primary, secondary, and post-hoc analyses and ties its main interpretation to phase 3 confirmation. The maximal-efficacy wording, confidence intervals extending beyond the reduction boundary, and demographic percentage error reduce reporting precision.

Summary, Findings and Interpretation; Statistical analysis; Discussion, dose-selection paragraphs
Positioning
3.8

The paper distinguishes FXIIa inhibition from existing prophylactic mechanisms and explicitly connects demographic and follow-up limitations to inference. Comparative positioning remains largely feature-based rather than a quantitative assessment against licensed alternatives.

Research in context; Discussion, prophylactic alternatives and limitations paragraphs

Reliability

Caveats4 of 4 checks


Results checkNoted

One reported value does not reconcile, but the key claims do not rest on it.

  • [Garadacimab] significantly reduced the monthly attack rate at 200 mg (100% [95% CI 98–101]) and 600 mg (93% [54–110]) versus placebo: "reduced by 93% [54–110]; p=0·0003" (Summary, Findings). The reported upper bounds of 101% and 110% exceed the feasible 100% reduction boundary, although an unconstrained interval can extend outside a parameter's feasible range without invalidating the efficacy test. → Conclusion holds
Reporting and transparencyNoted

The Results report an incorrect male percentage, while the participant count and arm-level counts agree. Ethics, consent, registration, sponsor involvement, conflicts, and conditional data access are declared.

Conflict of interest: declared · Ethics approval: declared · Preregistration: declared · Data availability: declared · Code availability: not stated

Reference IntegrityClean

25 references in manuscript 25 of 25 checkable references found in an index 2 references confirmed by manual review

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 02 Nov 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Metabolic and endocrine · Endocrine, metabolic, blood, and immune disorders
Type of advanceEmpirical
Route to useNamed
AdvanceAdvances
BeneficiariesCatch-all cause
CitationsNot available
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

A randomised placebo-controlled phase 2 trial showed the effect once in 32 patients over 12 weeks, and the authors state phase 3 confirmation is still warranted.

From the paper
“Garadacimab is an efficacious, subcutaneous prophylaxis in patients with HAE-C1-INH and warrants phase 3 evaluation.”

The paper names who would use the findings, patients with HAE-C1-INH receiving subcutaneous prophylaxis, but describes no specific prescribing decision or care setting.

Pathway

CSL Behring and clinical trial teams would confirm efficacy and safety in phase 3, after which allergists could prescribe monthly subcutaneous garadacimab to prevent attacks in HAE-C1-INH patients.

Barrier

The small 12-week phase 2 sample means long-term safety and efficacy must be confirmed in larger phase 3 trials before regulators will approve garadacimab for routine prophylaxis.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline

    Montagne, Nation, Sagare, et al. · 2020 · Clinical medicine

    Primary claim

    Our findings suggest that breakdown of the BBB contributes to APOE4-associated cognitive decline independently of Alzheimer's disease pathology, and might be a therapeutic target in APOE4 carriers.

    Tentative
    Evidence Score
    2.7±0.2
    Reliability
    Caveats
  2. Preeclampsia Affects Lipid Metabolism and HDL Function in Mothers and Their Offspring

    Stadler, Scharnagl, Wadsack, et al. · 2023 · Clinical medicine

    Primary claim

    early-onset, as well as late-onset, PE affect maternal and neonatal lipid metabolism, potentially contributing to disease manifestation and increased cardiovascular risk later in life

    Tentative
    Evidence Score
    2.8±0.1
    Reliability
    Caveats
  3. Clinical NEC prevention practices drive different microbiome profiles and functional responses in the preterm intestine

    Neumann, Mahnert, Kumpitsch, et al. · 2023 · Clinical medicine

    Primary claim

    We demonstrate that preventive regimens have the highest impact on development and maturation of the gastrointestinal microbiome, enabling the establishment of a resilient microbial ecosystem that reduces pathogenic threats in at-risk preterm infants.

    Tentative
    Evidence Score
    2.7±0.1
    Reliability
    Caveats

How the rubric works →